Attached files
| file | filename |
|---|---|
| 10-K - ANIKA THERAPEUTICS, INC. 10-K - Anika Therapeutics, Inc. | a6645325.htm |
| EX-31.1 - EXHIBIT 31.1 - Anika Therapeutics, Inc. | a6645325ex31_1.htm |
| EX-21.1 - EXHIBIT 21.1 - Anika Therapeutics, Inc. | a6645325ex21_1.htm |
| EX-32.1 - EXHIBIT 32.1 - Anika Therapeutics, Inc. | a6645325ex32_1.htm |
| EX-31.2 - EXHIBIT 31.2 - Anika Therapeutics, Inc. | a6645325ex31_2.htm |
| EX-10.34 - EXHIBIT 10.34 - Anika Therapeutics, Inc. | a6645325ex10_34.htm |
| EX-10.36 - EXHIBIT 10.36 - Anika Therapeutics, Inc. | a6645325ex10_36.htm |
| EX-10.33 - EXHIBIT 10.33 - Anika Therapeutics, Inc. | a6645325ex10_33.htm |
| EX-10.35 - EXHIBIT 10.35 - Anika Therapeutics, Inc. | a6645325ex10_35.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-63882, 333-06275, 333-66831, 333-79047, 333-58264, 333-110326 and 333-160102) of Anika Therapeutics, Inc. of our report dated March 16, 2011 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 16, 2011
-80-